First‑Line Therapy for Mild‑to‑Moderate Community‑Acquired Complicated Intra‑Abdominal Infections

Guideline Recommendations (IDSA/SIS)

• The 2010 IDSA/SIS guidelines recommend ertapenem as a preferred single‑agent therapy for mild‑to‑moderate community‑acquired complicated intra‑abdominal infections (A‑I evidence)【1】【2】【3】.
• The 2003 IDSA guidelines also list ertapenem for this indication【4】【5】.
• The IDSA/SIS Expert Panel cautions against using tigecycline for mild‑to‑moderate cases because its spectrum is excessively broad, covering MRSA and many organisms not typically involved in appendix‑derived infections【1】【2】【3】.
• Using agents intended for high‑severity infections in mild‑to‑moderate cases is discouraged due to higher toxicity risk and promotion of resistance (B‑II evidence)【1】【2】.

Indications for Ertapenem

• Appropriate for adult patients with community‑acquired complicated intra‑abdominal infection of mild‑to‑moderate severity【1】【2】【3】.
• Preferred when the infection source is appendiceal or colonic and requires anaerobic coverage【1】【2】.
• Suitable for patients with normal renal function【6】.
• Advantageous when once‑daily dosing (1 g IV every 24 h) is desired【6】【7】.

Indications for Tigecycline (Reserve Use)

• Considered for healthcare‑associated infections where multidrug‑resistant organisms are suspected【8】【9】.
• Reserved for patients with severe β‑lactam allergies that contraindicate carbapenems【1】【2】.
• May be used in high‑severity infections when ertapenem’s narrower spectrum is insufficient【1】【2】.

Antimicrobial Spectrum & Stewardship Concerns

• Broad use of ertapenem could accelerate emergence of carbapenem‑resistant Enterobacteriaceae, Pseudomonas, and Acinetobacter species【1】【2】.
• The risk is even greater with tigecycline because of its ultra‑broad activity, including MRSA coverage【1】【2】.
• Ertapenem does not provide reliable Pseudomonas coverage; for infections requiring anti‑pseudomonal activity, broader‑spectrum carbapenems (imipenem‑cilastatin, meropenem, doripenem) should be used【4】【6】.
• For high‑severity community‑acquired or healthcare‑associated infections, the preferred agents are the broader‑spectrum carbapenems rather than ertapenem or tigecycline【4】【6】【8】.

Dosing and Duration

Common Pitfalls to Avoid

• Do not use tigecycline as routine first‑line therapy for community‑acquired appendicitis or diverticulitis; this constitutes inappropriate antimicrobial stewardship and does not improve outcomes【1】【2】.
• Do not assume ertapenem covers Pseudomonas; select an anti‑pseudomonal carbapenem for such needs【4】【6】.

All facts are derived from IDSA/SIS guideline statements and associated evidence grades as cited.